White papers

The healthcare landscape is evolving, and integrated evidence planning (IEP) is becoming crucial for demonstrating the value of new treatments and expediting patient access. By incorporating the needs of all customer groups, IEP leads to faster approval, reimbursement, and access to care. It ensures efficient use of resources and generates holistic evidence for stakeholders like patients, ...

"Too much is never enough." "All things in moderation.” There’s a big gap between those two axioms. And for field forces in life sciences, that gap often creates a big debate: How much data is too much? Your reps want to be informed. They want to know the latest insights when they’re out detailing doctors. Next best action suggestions help. But… if you give them too much information (and change ...

When the FDA approves existing drugs for new uses, it can disrupt the marketplace – and companies need to know how to adapt to the new sales environment. Glucagon-like peptide-1 (GLP-1) drugs are disrupting the MedTech marketplace right now. Previously used to treat type 2 diabetes, these drugs are the latest weapon in the battle against obesity, and they are so effective that the number of ...

Literature reviews are a crucial part of life sciences research. They can reveal gaps in the existing research, provide information on unmet needs, and inform new market strategies. Even regulatory bodies rely heavily on literature reviews to help shape clinical guidelines and evaluate the effectiveness of treatments through statistical processes such as network meta-analysis. But there’s a catch ...

In the life sciences industry, traditional measurement tactics are falling short. They cannot address the complexities of the modern customer journey. The surge of digital channels and evolving customer behaviors are driving this difficulty. So how do you respond? This white paper redefines how life sciences companies approach omnichannel measurement. Authored by industry leaders Vandana Singh ...

Data drives everything we do today. At first glance, more data seems like a good thing. The more insight you have into something, the better the decisions you can craft. But that isn’t always the case. Too much information has proven overwhelming for many organizations, especially pharma companies. The rise of omnichannel marketing, where multiple avenues of reaching a consumer have been ...

Despite generating data an unprecedented rate, many life sciences companies still suffer from a lack of context. They have the data, they just don’t know what it means in the bigger picture. That means missed opportunities and missed revenue. Life sciences companies are now relying on embedded analytics to solve that. Instead of multiple applications, modern analyses can be baked into a single ...

As the life sciences industry becomes more data-driven, companies are harnessing advanced analytics to personalize interactions with healthcare professionals, patients, and stakeholders across multiple channels. In this scenario, identifying the best algorithm for omnichannel and the next best action (NBA) recommendations is crucial for optimizing customer engagement and achieving intended ...

Life sciences companies continually face the question of building or buying their critical data management solutions. Maximizing how far your dollars go and weighing the pros and cons of a build versus buy approach needs constant balance. While custom-built solutions offer the promise of more control, recurring investments create data silos, leading to ever-increasing costs to operate, maintain, ...